dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Spanjaart, Anne Mea |
dc.contributor.author | Ortiz-Maldonado, Valentín |
dc.contributor.author | Urbano-Ispizua, Alvaro |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Ljungman, Per |
dc.contributor.author | de la Camara, Rafael |
dc.contributor.author | Tridello, Gloria |
dc.date.accessioned | 2022-03-14T13:15:11Z |
dc.date.available | 2022-03-14T13:15:11Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hemato. Leukemia. 2021 Dec;35:3585–3588. |
dc.identifier.issn | 1476-5551 |
dc.identifier.uri | https://hdl.handle.net/11351/7164 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haematological cancer; Infectious diseases |
dc.description.abstract | COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients. For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to
severe morbidity and high mortality as compared to the general population [1–3]. For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still
limited to small case series and case reports [4–8]. CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present
the clinical course of COVID-19 in the largest European cohort to date. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Leukemia;35 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | COVID-19 (Malaltia) - Complicacions |
dc.subject | Cèl·lules B - Tumors |
dc.subject.mesh | Lymphoma, B-Cell |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | /complications |
dc.subject.mesh | Treatment Outcome |
dc.title | Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41375-021-01466-0 |
dc.subject.decs | linfoma de células B |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | /complicaciones |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1038/s41375-021-01466-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Spanjaart AM] Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam and LYMMCARE, Amsterdam, The Netherlands. [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska University Hospital Huddinge and Karolinska Comprehensive Cancer Center, Stockholm, Sweden. Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. [de La Camara R] Department of Hematology, Hospital Universitario de La Princesa, Madrid, Spain. [Tridello G] Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. [Ortiz-Maldonado V, Urbano-Ispizua A] Department of Hematology, Hospital Clínic, Barcelona, Spain. [Barba P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34750508 |
dc.identifier.wos | 000715634300001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/BDNS357800 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |